In total , 218 treatment-naive Chinese HBeAg-positive patients were randomized to peg-IFN alfa-2a ( 180 g/week ) for 48 weeks , either as monotherapy ( n = 72 ) , or with 24 weeks of ETV ( 0.5 mg/daily ) added at week 13 ( ETV add-on , n = 73 ) , or pretreatment with a 24-week course of ETV , starting peg-IFN alfa-2a at week 21 ( ETV pretreatment , n = 73 ) .